173 related articles for article (PubMed ID: 9416653)
41. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
[TBL] [Abstract][Full Text] [Related]
42. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.
Goff DC; Henderson DC; Amico E
Am J Psychiatry; 1992 Sep; 149(9):1189-94. PubMed ID: 1503131
[TBL] [Abstract][Full Text] [Related]
43. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment.
Wieselgren IM; Lindstrom LH
Acta Psychiatr Scand; 1996 Jan; 93(1):9-19. PubMed ID: 8919324
[TBL] [Abstract][Full Text] [Related]
44. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.
McEvoy JP; Hogarty GE; Steingard S
Arch Gen Psychiatry; 1991 Aug; 48(8):739-45. PubMed ID: 1883257
[TBL] [Abstract][Full Text] [Related]
45. Cognitive deficits and psychopathology in institutionalized versus community-dwelling elderly schizophrenia patients.
Evans JD; Negron AE; Palmer BW; Paulsen JS; Heaton RK; Jeste DV
J Geriatr Psychiatry Neurol; 1999; 12(1):11-5. PubMed ID: 10447149
[TBL] [Abstract][Full Text] [Related]
46. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up.
Remington GJ; Prendergast P; Bezchlibnyk-Butler KZ
Can J Psychiatry; 1997 Feb; 42(1):53-7. PubMed ID: 9040924
[TBL] [Abstract][Full Text] [Related]
47. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction.
Seidman LJ; Pepple JR; Faraone SV; Kremen WS; Green AI; Brown WA; Tsuang MT
Biol Psychiatry; 1993 Apr 15-May 1; 33(8-9):575-84. PubMed ID: 8101100
[TBL] [Abstract][Full Text] [Related]
48. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
[TBL] [Abstract][Full Text] [Related]
49. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices.
Peralta V; Cuesta MJ; Caro F; Martinez-Larrea A
Acta Psychiatr Scand; 1994 Nov; 90(5):354-7. PubMed ID: 7872040
[TBL] [Abstract][Full Text] [Related]
50. Neuroleptic nonresponse and affective symptoms: a 2-year prospective study of schizophrenic outpatients.
Faraone SV; Young AS; Brown WA
Psychiatry Res; 1989 Jun; 28(3):315-21. PubMed ID: 2569751
[TBL] [Abstract][Full Text] [Related]
51. [A differential approach to the improvement of prevention and correction of neuroleptic side extrapyramidal disorders with pantogam activ in patients with schizophrenia].
Tiganov AS; Panteleeva GP; Abramova LI; Bologov PV; Kananovich PS; Omel'chenko MA; Nikiforova IY
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):72-80. PubMed ID: 28374697
[TBL] [Abstract][Full Text] [Related]
52. Is neuroleptic dysphoria a healthy response?
Weiden PJ; Mann JJ; Dixon L; Haas G; DeChillo N; Frances AJ
Compr Psychiatry; 1989; 30(6):546-52. PubMed ID: 2573481
[TBL] [Abstract][Full Text] [Related]
53. Neuroleptic dose reduction in persistently psychotic patients.
Faraone SV; Green AI; Brown W; Yin P; Tsuang MT
Hosp Community Psychiatry; 1989 Nov; 40(11):1193-5. PubMed ID: 2572532
[No Abstract] [Full Text] [Related]
54. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.
Levinson DF; Simpson GM; Singh H; Yadalam K; Jain A; Stephanos MJ; Silver P
Arch Gen Psychiatry; 1990 Aug; 47(8):761-8. PubMed ID: 2378547
[TBL] [Abstract][Full Text] [Related]
55. Justifying neuroleptic drug treatment.
Overall JE; Garza-Trevino E; Rhoades HM; Volkow ND; Cecil S
Hosp Community Psychiatry; 1989 Jul; 40(7):749-51. PubMed ID: 2570741
[No Abstract] [Full Text] [Related]
56. Gender-related clinical differences in older patients with schizophrenia.
Lindamer LA; Lohr JB; Harris MJ; McAdams LA; Jeste DV
J Clin Psychiatry; 1999 Jan; 60(1):61-7; quiz 68-9. PubMed ID: 10074884
[TBL] [Abstract][Full Text] [Related]
57. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.
Shriqui CL
Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S38-48. PubMed ID: 8564916
[TBL] [Abstract][Full Text] [Related]
58. Psychopathology of early-onset versus late-onset schizophrenia revisited: an observation of 473 neuroleptic-naive patients before and after first-admission treatments.
Sato T; Bottlender R; Schröter A; Möller HJ
Schizophr Res; 2004 Apr; 67(2-3):175-83. PubMed ID: 14984876
[TBL] [Abstract][Full Text] [Related]
59. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia.
Pedersen CA; Gibson CM; Rau SW; Salimi K; Smedley KL; Casey RL; Leserman J; Jarskog LF; Penn DL
Schizophr Res; 2011 Oct; 132(1):50-3. PubMed ID: 21840177
[TBL] [Abstract][Full Text] [Related]
60. Attenuation of neuroleptic-induced extrapyramidal side effects by Kava special extract WS 1490.
Boerner RJ; Klement S
Wien Med Wochenschr; 2004 Nov; 154(21-22):508-10. PubMed ID: 15638068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
